Our Pharma Insights Blog
Every few months, someone in a regulatory affairs forum asks a version of the same…
The Ancillary Problem in Speciality Sourcing: A Market-Intelligence Look at Fintepla® (fenfluramine)
In specialty and comparator sourcing, the working assumption is that the molecule is the hard…
The clock on exclusivity doesn’t start when a patent expires; it starts the moment a…
The NCE-1 date for 𝗢𝗥𝗦𝗘𝗥𝗗𝗨® (𝗘𝗹𝗮𝗰𝗲𝘀𝘁𝗿𝗮𝗻𝘁) is January 27, 2027. While patent protection may extend…
When a new therapy enters the market, it frequently shifts the baseline standard of care,…
The FDA approvals in April 2026 introduced two important drugs that could create major opportunities.…
From vaccines to cancer therapy, biologics are transforming how we treat disease. They don’t just…
The FDA approved 5 drugs in March 2026. The approved drugs span across fields like…
With 1 drug approved in January 2026, we saw a great hike in the approval…
Understanding when a generic or biosimilar opportunity truly opens is rarely straightforward. Regulatory exclusivity and…
The rare disease landscape has hit a significant milestone early in 2026. On January 12th,…
One wrong decision when selecting an enteral feeding tube supplier can disrupt patient care overnight.…